tldrdaily.news logo

Arrowhead’s Gene-Silencing Drugs Show Promise in Obesity Treatment

1 min read
Source: statnews.com
Arrowhead’s Gene-Silencing Drugs Show Promise in Obesity Treatment
Photo: statnews.com
TL;DR Summary

Arrowhead Pharmaceuticals' gene-silencing drug candidate ARO-INHBE, in combination with Eli Lilly's Zepbound, showed promising early results in reducing weight and harmful visceral fat in obese patients with diabetes, potentially intensifying competition in weight loss drug development.

Topics:business#biotech#clinical-trials#gene-silencing#health#obesity#weight-loss
Share this article
  1. Arrowhead’s gene-silencing drugs cut fat in early obesity studies  statnews.com
  2. Arrowhead Drug Boosts Eli Lilly’s Zepbound Weight Loss in Early Trial  Barron's
  3. Why did ARWR stock surge over 15% pre-market today?  MSN
  4. Arrowhead takes aim at obesity market with early data on dual gene silencing assets  Fierce Biotech
  5. Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study  BioSpace

Reading Insights

Total Reads

0

Unique Readers

4

Time Saved

1 min

vs 2 min read

Condensed

83%

211 → 36 words

Want the full story? Read the original article

Read on statnews.com